From #EASD2026 - People with type 2 diabetes have a significantly higher risk for developing cancer than those without the condition.

Full story 👉️ buff.ly/LQRL58n

#T2D #MedNews

From #EASD2026 - Prof. Elif Ekinci shares the efficacy and safety findings from TRIUMPH-2, a phase 3 trial of the GIP, GLP-1, and glucagon receptor agonist #retatrutide in patients with type 2 diabetes and obesity.

Watch the full interview 👉️ buff.ly/sivRg5m

#DiabetesCare

💙👇 Our 62nd Annual Meeting in #words!

“Diabetes”, “#EASD2026” & “Milan” took centre stage in this word cloud - built from words used in posts throughout the Annual Meeting week, it captures the breadth of topics discussed.

Grazie, Milano! Thank you to everyone who engaged with us! 🇮🇹

TRIUMPH-2 findings suggest that retatrutide might advance the treatment of people with obesity and type 2 diabetes, showing bodyweight reduction alongside improvements in glycaemic control and cardiometabolic risk factors. Read more: spkl.io/633207VNIE #EASD2026

At #EASD2026, EUDF hosted a symposium on the EU Safe Hearts Plan.

Key message: we need integrated, person-centred care, stronger support for HCPs, better prevention and early detection closer to people.

Now, implementation is key.

Watch the session compilation video to learn more.

See the updated ADA and EASD consensus report on the management of #type2diabetes #EASD2026 link.springer.com/article/10.1... 🔓

What’s the most important unanswered question in diabetes research?

At #EASD2026, Dr. Denise Faustman shared why looking beyond blood glucose matters, and how metabolomics can help resolve the underlying biology.

▶️ Watch her perspective.

#EASD2026 came to a successful close! 👏
It was a pleasure to welcome our Editorial Board Member, Dr. Laura Marroquí Esclapez, at our booth! We greatly appreciate her support and valuable contributions & look forward to continuing our collaboration in #Biomedicines!🤝

SIBIONICS and PharmaSens Discover New Frontiers in Automated Insulin Management at EASD 2026 #None #Milano #SIBIONICS #PharmaSens #EASD2026

#EASD2026 has wrapped up! 👏
It was a pleasure to meet our Guest Editor, Dr. Tomislav Bulum, at our booth! We appreciate his support and valuable contribution and we look forward to continuing our collaboration and working together! 🤝
#Conference #Biomedicines

Catch up on the latest advances in #diabetes research, treatment, and care from #EASD2026 with our hub page.

👉️ buff.ly/7GIjfiy

#MedSky

📢 El 8 de octubre, revisaremos los principales avances del #EASD2026 en diabetes: tecnología en DM1 y DM2, nuevas dianas terapéuticas, enfermedad cardiorrenal, obesidad, medicina de precisión y más.

👉 https://f.mtr.cool/coi9c6nas1

🎥💙 The #EASD2026 Annual Meeting may be over, but the conversations continue.

We asked delegates why they do what they do: 60 seconds each, 1️⃣thing in common: they all want to help people.

🎬👇 Watch "Human Behind Science" & meet the people behind the research.

www.linkedin.com/posts/easd_e...

🔬 DZD at EASD 2026:A short photo review
Exciting research, inspiring scientific sessions, prestigious awards and many valuable conversations at the DZD booth. Thank you to everyone who visited us and helped make #EASD2026 such a special event!
📸 A short photo review
#DZD #DiabetesResearch

From #EASD2026 - The long-acting amylin analog petrelintide is well tolerated and can achieve clinically and statistically significant weight loss in people with #obesity compared with placebo.

👉️ buff.ly/BlrCa0G

#MedNews

🙌Last week, at #EASD2026, we brought together PwD, HCPs & other experts to discuss the future of diabetes education in the #AI era.

From digital tools to personalised support, the event sparked interesting reflections on how diabetes education can evolve to better support PwD.

💉 #obesity #EASD2026

🇺🇸 $LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 $ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.

All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/

EASO was delighted to join colleagues from EASD, ESC and EUDF and welcome EU Health Commissioner Oliver Varhelyi to launch #EUScreeningWeek in Milano at #EASD2026. View the press event: audiovisual.ec.europa.eu/en/media/vid...

Read the press release: easo.org/eu-screening...

At #EASD2026 in Milan this week, a dazzling show of new data on obesity and diabetes fits a broader picture looking beyond weight outcomes to health outcomes.
HT: @elilillyandcompany.bsky.social @novonordisk.bsky.social @regeneron.com @boehringerglobal.bsky.social
conscienhealth.org/2026/10/03/e...

1️⃣week. 1️⃣ global #diabetes community. 16,000+ delegates! Thank you all for being part of #EASD2026! 🙏

👇 Take one final look at our highlights & look ahead…

🔔 Save the date for #EASD2027 in Budapest! 🇭🇺
📅 20 - 24 Sept 2027 |📍 Hungexpo Budapest Congress Centre

🎥 www.linkedin.com/feed/update/...